A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  Berenstein, Ariel José ^a,b   Magariños, María Paula ^c,d   Chernomoretz, Ariel ^a,b   Agüero, Fernán ^c  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

^d EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; PEPTIDE DEFORMYLASE; ANTIPARASITIC AGENT;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG REPOSITIONING; GENOME; HIGH THROUGHPUT SCREENING; KINETOPLASTIDA; MATHEMATICAL COMPUTING; NEGLECTED DISEASE; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN ANALYSIS; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TRYPANOSOMA CRUZI; ANIMAL; BIOLOGY; DRUG DEVELOPMENT; HUMAN; ISOLATION AND PURIFICATION; MOUSE; NEGLECTED DISEASES; PROCEDURES;

ANIMALS; ANTIPARASITIC AGENTS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; MICE; NEGLECTED DISEASES;

EID: 84957110740     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004300     Document Type: Article

References (126)

1. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359: 2188–2194. 12090998
2. Hotez PJP, Molyneux DDH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. http://www.nejm.org/doi/full/10.1056/NEJMra064142. 17804846
3. Buscaglia CA, Kissinger JC, Agüero F, (2015) Neglected Tropical Diseases in the Post-Genomic Era. Trends Genet 31: 539–555. http://www.cell.com/article/S0168952515001134/fulltext. Accessed 7 October 2015. doi: 10.1016/j.tig.2015.06.002 26450337
4. Wyatt PG, Gilbert IH, Read KD, Fairlamb AH, (2011) Target validation: linking target and chemical properties to desired product profile. Curr Top Med Chem 11: 1275–1283. 21401506
5. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. J Heal Econ 22: 151–185. http://dx.doi.org/10.1016/S0167-6296(02)00126-1.
6. Kola I, Landis J, (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711–715. http://dx.doi.org/10.1038/nrd1470. 15286737
7. Robertson SA, Renslo AR, (2011) Drug discovery for neglected tropical diseases at the Sandler Center. Futur Med Chem 3: 1279–1288. http://dx.doi.org/10.4155/fmc.11.85.
8. Kesselheim AS, Darrow JJ, (2014) Drug development and FDA approval, 1938–2013. N Engl J Med 370: e39. http://www.ncbi.nlm.nih.gov/pubmed/24963591. Accessed 27 April 2015. doi: 10.1056/NEJMp1402114 24963591
9. Ashburn TT, Thor KB, (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673–683. http://dx.doi.org/10.1038/nrd1468. 15286734
10. Chong CR, Sullivan DJ, Jr (2007) New uses for old drugs. Nature 448: 645–646. http://dx.doi.org/10.1038/448645a. 17687303
11. Novac N, (2013) Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 34: 267–272. doi: http://dx.doi.org/10.1016/j.tips.2013.03.004 23582281
12. Teo SK, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, et al. (2002) Thalidomide in the treatment of leprosy. Microbes Infect 4: 1193–1202. 12361920
13. Haupt VJ, Schroeder M, (2011) Old friends in new guise: repositioning of known drugs with structural bioinformatics. Br Bioinform 12: 312–326. http://dx.doi.org/10.1093/bib/bbr011.
14. Pollastri MP, Campbell RK, (2011) Target repurposing for neglected diseases. Futur Med Chem 3: 1307–1315. http://dx.doi.org/10.4155/fmc.11.92.
15. Jin G, Wong STC, (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19: 637–644. http://dx.doi.org/10.1016/j.drudis.2013.11.005. doi: 10.1016/j.drudis.2013.11.005 24239728
16. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science (80-) 321: 263–266. http://dx.doi.org/10.1126/science.1158140. doi: 10.1126/science.1158140 18621671
17. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197–206. http://dx.doi.org/10.1038/nbt1284. 17287757
18. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175–181. http://dx.doi.org/10.1038/nature08506. doi: 10.1038/nature08506 19881490
19. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621–14626. http://dx.doi.org/10.1073/pnas.1000138107. doi: 10.1073/pnas.1000138107 20679242
20. Meslamani J, Bhajun R, Martz F, Rognan D, (2013) Computational profiling of bioactive compounds using a target-dependent composite workflow. J Chem Inf Model 53: 2322–2333. http://dx.doi.org/10.1021/ci400303n. doi: 10.1021/ci400303n 23941602
21. Parkkinen JA, Kaski S, (2014) Probabilistic drug connectivity mapping. BMC Bioinformatics 15: 113. http://dx.doi.org/10.1186/1471-2105-15-113. doi: 10.1186/1471-2105-15-113 24742351
22. Iskar M, Zeller G, Blattmann P, Campillos M, Kuhn M, et al. (2013) Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Mol Syst Biol 9: 662. http://dx.doi.org/10.1038/msb.2013.20. doi: 10.1038/msb.2013.20 23632384
23. Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, et al. (2013) Drug target prediction and repositioning using an integrated network-based approach. PLoS One 8: e60618. http://dx.doi.org/10.1371/journal.pone.0060618. doi: 10.1371/journal.pone.0060618 23593264
24. Lo Y-C, Senese S, Li C-M, Hu Q, Huang Y, et al. (2015) Large-Scale Chemical Similarity Networks for Target Profiling of Compounds Identified in Cell-Based Chemical Screens. PLoS Comput Biol 11: e1004153. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4380459&tool=pmcentrez&rendertype=abstract. Accessed 1 April 2015. doi: 10.1371/journal.pcbi.1004153 25826798
25. Kruger FA, Overington JP, (2012) Global analysis of small molecule binding to related protein targets. PLoS Comput Biol 8: e1002333. http://dx.doi.org/10.1371/journal.pcbi.1002333. doi: 10.1371/journal.pcbi.1002333 22253582
26. Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900–907. http://dx.doi.org/10.1038/nrd2684. doi: 10.1038/nrd2684 18927591
27. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, et al. (2010) Identification of attractive drug targets in neglected-disease pathogens using an [i]in silico[/i] approach. PLoS Negl Trop Dis 4: e804. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2927427&tool=pmcentrez&rendertype=abstract. Accessed 4 October 2010. doi: 10.1371/journal.pntd.0000804 20808766
28. Magariños MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, et al. (2012) TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res 40: D1118–D1127. http://dx.doi.org/10.1093/nar/gkr1053. doi: 10.1093/nar/gkr1053 22116064
29. Gamo F-J, Sanz LM, Vidal J, de Cozar C, Alvarez E, et al. (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465: 305–310. http://dx.doi.org/10.1038/nature09107. Accessed 22 July 2010. doi: 10.1038/nature09107 20485427
30. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, et al. (2010) Chemical genetics of Plasmodium falciparum. Nature 465: 311–315. http://dx.doi.org/10.1038/nature09099. doi: 10.1038/nature09099 20485428
31. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TNC, et al. (2013) The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One 8: e62906. http://dx.doi.org/10.1371/journal.pone.0062906. doi: 10.1371/journal.pone.0062906 23798988
32. Cheng F, Liu C, Jiang J, Lu W, Li W, et al. (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8: e1002503. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3349722&tool=pmcentrez&rendertype=abstract. doi: 10.1371/journal.pcbi.1002503 22589709
33. Alaimo S, Pulvirenti A, Giugno R, Ferro A, (2013) Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics 29: 2004–2008. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3722516&tool=pmcentrez&rendertype=abstract. doi: 10.1093/bioinformatics/btt307 23720490
34. Csermely P, Agoston V, Pongor S, (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178–182. http://dx.doi.org/10.1016/j.tips.2005.02.007. 15808341
35. Harrold JM, Ramanathan M, Mager DE, (2013) Network-based approaches in drug discovery and early development. Clin Pharmacol Ther 94: 651–658. http://www.ncbi.nlm.nih.gov/pubmed/24025802. Accessed 5 May 2015. doi: 10.1038/clpt.2013.176 24025802
36. Yabuuchi H, Niijima S, Takematsu H, Ida T, Hirokawa T, et al. (2011) Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol Syst Biol 7: 472. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3094066&tool=pmcentrez&rendertype=abstract. Accessed 5 May 2015. doi: 10.1038/msb.2011.5 21364574
37. Yamanishi Y, Kotera M, Kanehisa M, Goto S, (2010) Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26: i246–i254. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2881361&tool=pmcentrez&rendertype=abstract. Accessed 31 March 2015. doi: 10.1093/bioinformatics/btq176 20529913
38. van Laarhoven T, Marchiori E, (2013) Predicting Drug-Target Interactions for New Drug Compounds Using a Weighted Nearest Neighbor Profile. PLoS One 8: e66952. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3694117&tool=pmcentrez&rendertype=abstract. Accessed 5 May 2015. 23840562
39. Martínez-Jiménez F, Marti-Renom MA, (2015) Ligand-Target Prediction by Structural Network Biology Using nAnnoLyze. PLOS Comput Biol 11: e1004157. http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004157. Accessed 30 March 2015. doi: 10.1371/journal.pcbi.1004157 25816344
40. Yamanishi Y, Kotera M, Moriya Y, Sawada R, Kanehisa M, et al. (2014) DINIES: drug-target interaction network inference engine based on supervised analysis. Nucleic Acids Res 42: W39–W45. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086078&tool=pmcentrez&rendertype=abstract. Accessed 21 July 2015. doi: 10.1093/nar/gku337 24838565
41. Jones P, Binns D, Chang H-Y, Fraser M, Li W, et al. (2014) InterProScan 5: genome-scale protein function classification. Bioinformatics 30: 1236–1240. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3998142&tool=pmcentrez&rendertype=abstract. Accessed 13 July 2014. doi: 10.1093/bioinformatics/btu031 24451626
42. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M, (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40: D109–D114. http://dx.doi.org/10.1093/nar/gkr988. doi: 10.1093/nar/gkr988 22080510
43. Chen F, Mackey AJ, Stoeckert CJ, JrRoos DS, (2006) OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. Nucleic Acids Res 34: D363–D368. http://dx.doi.org/10.1093/nar/gkj123. 16381887
44. Fischer S, Brunk BP, Chen F, Gao X, Harb OS, et al. (2011) Using OrthoMCL to Assign Proteins to OrthoMCL-DB Groups or to Cluster Proteomes Into New Ortholog Groups. Curr Protoc Bioinforma Chapter 6: Unit6.12. http://dx.doi.org/10.1002/0471250953.bi0612s35.
45. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100–D1107. http://dx.doi.org/10.1093/nar/gkr777. doi: 10.1093/nar/gkr777 21948594
46. Haider N, (2010) Functionality pattern matching as an efficient complementary structure/reaction search tool: an open-source approach. Molecules 15: 5079–5092. http://dx.doi.org/10.3390/molecules15085079. doi: 10.3390/molecules15085079 20714286
47. Willett P, Barnard JM, Downs GM, (1998) Chemical Similarity Searching. J Chem Inf Model 38: 983–996. http://dx.doi.org/10.1021/ci9800211. Accessed 11 September 2015.
48. Baldi P, Nasr R, (2010) When is chemical similarity significant? the statistical distribution of chemical similarity scores and its extreme values. J Chem Inf Model 50: 1205–1222. doi: 10.1021/ci100010v 20540577
49. Martin YC, Kofron JL, Traphagen LM, (2002) Do structurally similar molecules have similar biological activity? J Med Chem 45: 4350–4358. 12213076
50. Gagaring K, Borboa R, Francek C, Chen Z, Buenviaje J, et al. (2010) Novartis-GNF Malaria Box. https://www.ebi.ac.uk/chemblntd.
51. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, et al. (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42: D1091–D1097. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3965102&tool=pmcentrez&rendertype=abstract. Accessed 20 July 2014. doi: 10.1093/nar/gkt1068 24203711
52. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, et al. (2014) Pfam: The protein families database. Nucleic Acids Res 42.
53. Li L, Stoeckert CJ, Roos DS, (2003) OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res 13: 2178–2189. http://dx.doi.org/10.1101/gr.1224503. 12952885
54. Chen F, Mackey AJ, Vermunt JK, Roos DS, (2007) Assessing performance of orthology detection strategies applied to eukaryotic genomes. PLoS One 2: e383. http://dx.doi.org/10.1371/journal.pone.0000383. 17440619
55. Faust K, (1997) Centrality in affiliation networks. Soc Networks 19: 157–191. http://www.sciencedirect.com/science/article/pii/S0378873396003000.
56. Newman M, (2010) Networks: An Introduction. 1st Editio. Oxford: Oxford University Press. 720 p.
57. Pearson WR, (2000) Flexible sequence similarity searching with the FASTA3 program package. Methods Mol Biol 132: 185–219. 10547837
58. McClish DK, (1989) Analyzing a portion of the ROC curve. Med Decis Making 9: 190–195. http://www.ncbi.nlm.nih.gov/pubmed/2668680. Accessed 21 October 2014. 2668680
59. Gillis J, Pavlidis P, (2011) The role of indirect connections in gene networks in predicting function. Bioinformatics 27: 1860–1866. http://dx.doi.org/10.1093/bioinformatics/btr288. doi: 10.1093/bioinformatics/btr288 21551147
60. Nabieva E, Jim K, Agarwal A, Chazelle B, Singh M, (2005) Whole-proteome prediction of protein function via graph-theoretic analysis of interaction maps. Bioinformatics 21 Suppl 1: i302–i310. http://dx.doi.org/10.1093/bioinformatics/bti1054. 15961472
61. Kissinger JC, (2006) A tale of three genomes: the kinetoplastids have arrived. Trends Parasitol 22: 240–243. 16635586
62. Hanks S, Hunter T, (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576–596. http://www.fasebj.org/content/9/8/576.abstract. Accessed 10 April 2015. 7768349
63. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130–137. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2880454&tool=pmcentrez&rendertype=abstract. Accessed 5 November 2015. doi: 10.1038/nrc2787 20094047
64. Bao Y, Weiss LM, Braunstein VL, Huang H, (2008) Role of protein kinase A in Trypanosoma cruzi. Infect Immun 76: 4757–4763. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2546855&tool=pmcentrez&rendertype=abstract. Accessed 17 December 2014. doi: 10.1128/IAI.00527-08 18694966
65. Bao Y, Weiss LM, Ma YF, Kahn S, Huang H, (2010) Protein kinase A catalytic subunit interacts and phosphorylates members of trans-sialidase super-family in Trypanosoma cruzi. Microbes Infect 12: 716–726. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2934751&tool=pmcentrez&rendertype=abstract. Accessed 17 December 2014. doi: 10.1016/j.micinf.2010.04.014 20466066
66. Allocco JJ, Donald R, Zhong T, Lee A, Tang YS, et al. (2006) Inhibitors of casein kinase 1 block the growth of Leishmania major promastigotes in vitro. Int J Parasitol 36: 1249–1259. http://www.ncbi.nlm.nih.gov/pubmed/16890941. Accessed 17 December 2014. 16890941
67. Marhadour S, Marchand P, Pagniez F, Bazin M-A, Picot C, et al. (2012) Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. Eur J Med Chem 58: 543–556. http://www.ncbi.nlm.nih.gov/pubmed/23164660. Accessed 17 December 2014. doi: 10.1016/j.ejmech.2012.10.048 23164660
68. Spadafora C, Repetto Y, Torres C, Pino L, Robello C, et al. Two casein kinase 1 isoforms are differentially expressed in Trypanosoma cruzi. Mol Biochem Parasitol 124: 23–36. http://www.ncbi.nlm.nih.gov/pubmed/12387847. Accessed 17 December 2014. 12387847
69. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, et al. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol 7: 411–422. http://www.ncbi.nlm.nih.gov/pubmed/10873834. Accessed 17 December 2014. 10873834
70. Bao Y, Weiss LM, Ma YF, Lisanti MP, Tanowitz HB, et al. (2010) Molecular cloning and characterization of mitogen-activated protein kinase 2 in Trypanosoma cruzi. Cell Cycle 9: 2888–2896. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3040964&tool=pmcentrez&rendertype=abstract. Accessed 17 December 2014. 20603604
71. Patterson RL, Boehning D, Snyder SH, (2004) Inositol 1,4,5-trisphosphate receptors as signal integrators. Annu Rev Biochem 73: 437–465. 15189149
72. Huang G, Bartlett PJ, Thomas AP, Moreno SNJ, Docampo R, (2013) Acidocalcisomes of Trypanosoma brucei have an inositol 1,4,5-trisphosphate receptor that is required for growth and infectivity. Proc Natl Acad Sci U S A 110: 1887–1892. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3562765&tool=pmcentrez&rendertype=abstract. doi: 10.1073/pnas.1216955110 23319604
73. Hashimoto M, Enomoto M, Morales J, Kurebayashi N, Sakurai T, et al. (2013) Inositol 1,4,5-trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist Trypanosoma cruzi. Mol Microbiol 87: 1133–1150. http://dx.doi.org/10.1111/mmi.12155. doi: 10.1111/mmi.12155 23320762
74. Bahia D, Oliveira LM, Lima FM, Oliveira P, Silveira JF da, et al. (2009) The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei,} rypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum—new tools for designing specific inhibitors. Biochem Biophys Res Commun 390: 963–970. doi: http://dx.doi.org/10.1016/j.bbrc.2009.10.086 19852933
75. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, et al. (2011) Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 54: 7579–7587. http://dx.doi.org/10.1021/jm2009327. doi: 10.1021/jm2009327 21981714
76. Woolsey AM, Sunwoo L, Petersen CA, Brachmann SM, Cantley LC, et al. (2003) Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation. J Cell Sci 116: 3611–3622. d 12876217
77. Andrade LO, Andrews NW, (2004) Lysosomal fusion is essential for the retention of Trypanosoma cruzi inside host cells. J Exp Med 200: 1135–1143. 15520245
78. Schoijet AC, Miranda K, Girard-Dias W, de Souza W, Flawiá MM, et al. (2008) A Trypanosoma cruzi phosphatidylinositol 3-kinase (TcVps34) is involved in osmoregulation and receptor-mediated endocytosis. J Biol Chem 283: 31541–31550. http://dx.doi.org/10.1074/jbc.M801367200. doi: 10.1074/jbc.M801367200 18801733
79. Hashimoto M, Morales J, Fukai Y, Suzuki S, Takamiya S, et al. (2012) Critical importance of the de novo pyrimidine biosynthesis pathway for Trypanosoma cruzi growth in the mammalian host cell cytoplasm. Biochem Biophys Res Commun 417: 1002–1006. doi: 10.1016/j.bbrc.2011.12.073 22209850
80. Cosentino RO, Agüero F, (2014) Genetic Profiling of the Isoprenoid and Sterol Biosynthesis Pathway Genes of Trypanosoma cruzi. PLoS One 9: e96762. http://dx.doi.org/10.1371/journal.pone.0096762. doi: 10.1371/journal.pone.0096762 24828104
81. Lepesheva GI, Zaitseva NG, Nes WD, Zhou W, Arase M, et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B’ helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 281: 3577–3585. http://dx.doi.org/10.1074/jbc.M510317200. 16321980
82. Lepesheva GI, Park H-W, Hargrove TY, Vanhollebeke B, Wawrzak Z, et al. (2010) Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J Biol Chem 285: 1773–1780. http://dx.doi.org/10.1074/jbc.M109.067470. doi: 10.1074/jbc.M109.067470 19923211
83. Andrade-Neto VV, Matos-Guedes HL de, Gomes DC de O, Canto-Cavalheiro MM do, Rossi-Bergmann B, et al. (2012) The stepwise selection for ketoconazole resistance induces upregulation of C14-demethylase (CYP51) in Leishmania amazonensis. Mem Inst Oswaldo Cruz 107: 416–419. 22510839
84. Tate EW, Bell AS, Rackham MD, Wright MH, (2014) N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. Parasitology 141: 37–49. http://dx.doi.org/10.1017/S0031182013000450. doi: 10.1017/S0031182013000450 23611109
85. Sheng C, Zhu J, Zhang W, Zhang M, Ji H, et al. (2007) 3D-QSAR and molecular docking studies on benzothiazole derivatives as Candida albicans N-myristoyltransferase inhibitors. Eur J Med Chem 42: 477–486. doi: http://dx.doi.org/10.1016/j.ejmech.2006.11.001 17349719
86. Rackham MD, Brannigan JA, Rangachari K, Meister S, Wilkinson AJ, et al. (2014) Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP). J Med Chem 57: 2773–2788. http://dx.doi.org/10.1021/jm500066b. doi: 10.1021/jm500066b 24641010
87. Wright MH, Clough B, Rackham MD, Rangachari K, Brannigan JA, et al. (2014) Validation of N -myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. Nat Chem 6: 112–121. http://dx.doi.org/10.1038/nchem.1830. doi: 10.1038/nchem.1830 24451586
88. Bowyer PW, Gunaratne RS, Grainger M, Withers-Martinez C, Wickramsinghe SR, et al. (2007) Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J 408: 173–180. http://dx.doi.org/10.1042/BJ20070692. 17714074
89. Calí P, Naerum L, Mukhija S, Hjelmencrantz A, (2004) Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Bioorg Med Chem Lett 14: 5997–6000. http://www.sciencedirect.com/science/article/pii/S0960894X04012119. Accessed 17 December 2014. 15546716
90. Wiesner J, Sanderbrand S, Altincicek B, Beck E, Jomaa H, (2001) Seeking new targets for antiparasitic agents. Trends Parasitol 17: 7–8. http://www.ncbi.nlm.nih.gov/pubmed/11394347. Accessed 20 October 2014.
91. Hynes JB, (1970) Hydroxylamine derivatives as potential antimalarial agents. 1. Hydroxamic acids. J Med Chem 13: 1235–1237. http://dx.doi.org/10.1021/jm00300a056. Accessed 29 April 2015. 5479878
92. Gupta S, , editor (2013) Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities. Berlin: Springer Science & Business Media. 312 p. Available: http://www.springer.com/us/book/9783642381102. Accessed 5 November 2015.
93. McGowan S, (2013) Sitagliptin does not inhibit the M1 alanyl aminopeptidase from Plasmodium falciparum. Bioinformation 9: 661–662. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3732437&tool=pmcentrez&rendertype=abstract. Accessed 18 December 2014. doi: 10.6026/97320630009661 23930016
94. Skinner-Adams TS, Stack CM, Trenholme KR, Brown CL, Grembecka J, et al. (2010) Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends Biochem Sci 35: 53–61. http://www.ncbi.nlm.nih.gov/pubmed/19796954. Accessed 27 August 2015. doi: 10.1016/j.tibs.2009.08.004 19796954
95. Flipo M, Florent I, Grellier P, Sergheraert C, Deprez-Poulain R, (2003) Design, synthesis and antimalarial activity of novel, quinoline-Based, zinc metallo-aminopeptidase inhibitors. Bioorg Med Chem Lett 13: 2659–2662. http://www.sciencedirect.com/science/article/pii/S0960894X0300550X. Accessed 27 April 2015. 12873488
96. Harbut MB, Velmourougane G, Dalal S, Reiss G, Whisstock JC, et al. (2011) Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases. Proc Natl Acad Sci U S A 108: E526–E534. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3161592&tool=pmcentrez&rendertype=abstract. Accessed 18 December 2014. doi: 10.1073/pnas.1105601108 21844374
97. Kannan Sivaraman K, Paiardini A, Sieńczyk M, Ruggeri C, Oellig CA, et al. (2013) Synthesis and structure-activity relationships of phosphonic arginine mimetics as inhibitors of the M1 and M17 aminopeptidases from Plasmodium falciparum. J Med Chem 56: 5213–5217. http://www.ncbi.nlm.nih.gov/pubmed/23713488. Accessed 18 December 2014. doi: 10.1021/jm4005972 23713488
98. Poreba M, McGowan S, Skinner-Adams TS, Trenholme KR, Gardiner DL, et al. (2012) Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum. PLoS One 7: e31938. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3281095&tool=pmcentrez&rendertype=abstract. Accessed 27 August 2015. doi: 10.1371/journal.pone.0031938 22359643
99. Belluti F, Perozzo R, Lauciello L, Colizzi F, Kostrewa D, et al. (2013) Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI). J Med Chem 56: 7516–7526. http://www.ncbi.nlm.nih.gov/pubmed/24063369. Accessed 18 December 2014. doi: 10.1021/jm400637m 24063369
100. Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, et al. (2001) 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg Med Chem Lett 11: 2061–2065. http://www.ncbi.nlm.nih.gov/pubmed/11514139. Accessed 15 April 2015. 11514139
101. am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, et al. (2008) Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett 18: 3029–3033. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2491328&tool=pmcentrez&rendertype=abstract. Accessed 27 April 2015. doi: 10.1016/j.bmcl.2008.04.038 18457948
102. Samal RP, Khedkar VM, Pissurlenkar RRS, Bwalya AG, Tasdemir D, et al. (2013) Design, synthesis, structural characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-ray diffraction and evaluation of a new class of phenylaminoacetic acid benzylidene hydrazines as pfENR inhibitors. Chem Biol Drug Des 81: 715–729. http://www.ncbi.nlm.nih.gov/pubmed/23398677. Accessed 18 December 2014. doi: 10.1111/cbdd.12118 23398677
103. Schrader FC, Glinca S, Sattler JM, Dahse H-M, Afanador GA, et al. (2013) Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. ChemMedChem 8: 442–461. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3633473&tool=pmcentrez&rendertype=abstract. Accessed 18 December 2014. doi: 10.1002/cmdc.201200407 23341167
104. Muhammad A, Anis I, Ali Z, Awadelkarim S, Khan A, et al. (2012) Methylenebissantin: a rare methylene-bridged bisflavonoid from Dodonaea viscosa which inhibits Plasmodium falciparum enoyl-ACP reductase. Bioorg Med Chem Lett 22: 610–612. http://www.ncbi.nlm.nih.gov/pubmed/22082562. Accessed 18 December 2014. doi: 10.1016/j.bmcl.2011.10.072 22082562
105. Muench SP, Stec J, Zhou Y, Afanador GA, McPhillie MJ, et al. (2013) Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett 23: 3551–3555. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3683578&tool=pmcentrez&rendertype=abstract. Accessed 18 December 2014. doi: 10.1016/j.bmcl.2013.04.035 23664871
106. Guggisberg AM, Amthor RE, Odom AR, (2014) Isoprenoid biosynthesis in Plasmodium falciparum. Eukaryot Cell 13: 1348–1359. http://ec.asm.org/content/13/11/1348.abstract. Accessed 25 August 2015. doi: 10.1128/EC.00160-14 25217461
107. Lindner SE, Sartain MJ, Hayes K, Harupa A, Moritz RL, et al. (2014) Enzymes involved in plastid-targeted phosphatidic acid synthesis are essential for P lasmodium yoelii liver-stage development. Mol Microbiol 91: 679–693. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3925071&tool=pmcentrez&rendertype=abstract. Accessed 18 March 2015. doi: 10.1111/mmi.12485 24330260
108. Kumar S, Chaudhary K, Foster JM, Novelli JF, Zhang Y, et al. (2007) Mining predicted essential genes of brugia malayi for nematode drug targets. PLoS One 2: e1189. http://dx.doi.org/10.1371/journal.pone.0001189. 18000556
109. Chen Y, Xu R, (2015) Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery. BMC Genomics 16 Suppl 7: S9. http://www.biomedcentral.com/1471-2164/16/S7/S9. Accessed 27 August 2015. doi: 10.1186/1471-2164-16-S7-S9 26099491
110. Morel C, Ibarz G, Oiry C, Carnazzi E, Bergé G, et al. (2005) Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase. J Biol Chem 280: 21384–21393. http://www.ncbi.nlm.nih.gov/pubmed/15772081. Accessed 5 November 2015. 15772081
111. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055–4063. http://www.ncbi.nlm.nih.gov/pubmed/17720881. Accessed 5 November 2015. 17720881
112. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung C-Y, et al. (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 7: 3490–3498. http://www.ncbi.nlm.nih.gov/pubmed/19001433. Accessed 5 November 2015. doi: 10.1158/1535-7163.MCT-08-0826 19001433
113. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, et al. (2005) An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol 3: e128. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1073692&tool=pmcentrez&rendertype=abstract. Accessed 5 November 2015. 15799708
114. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035–1044. http://dx.doi.org/10.1038/nbt1328. Accessed 14 August 2015. 17721511
115. Anighoro A, Bajorath J, Rastelli G, (2014) Polypharmacology: Challenges and Opportunities in Drug Discovery. J Med Chem 57: 7874–7887. http://dx.doi.org/10.1021/jm5006463. Accessed 12 March 2015. doi: 10.1021/jm5006463 24946140
116. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175–181. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2784146&tool=pmcentrez&rendertype=abstract. Accessed 5 April 2015. doi: 10.1038/nature08506 19881490
117. Kaiser M, Mäser P, Tadoori LP, Ioset J-R, Brun R, (2015) Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning. PLoS One 10: e0135556. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135556. Accessed 31 August 2015. doi: 10.1371/journal.pone.0135556 26270335
118. Kodadek T, (2010) Rethinking screening. Nat Chem Biol 6: 162–165. http://www.ncbi.nlm.nih.gov/pubmed/20154660. Accessed 20 October 2014. 20154660
119. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, et al. (2015) The promise and peril of chemical probes. Nat Chem Biol 11: 536–541. http://dx.doi.org/10.1038/nchembio.1867. Accessed 22 July 2015. doi: 10.1038/nchembio.1867 26196764
120. Peña I, Pilar Manzano M, Cantizani J, Kessler A, Alonso-Padilla J, et al. (2015) New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep 5: 8771. http://www.nature.com/srep/2015/150305/srep08771/full/srep08771.html. Accessed 27 May 2015. doi: 10.1038/srep08771 25740547
121. Tsai IJ, Zarowiecki M, Holroyd N, Garciarrubio A, Sanchez-Flores A, et al. (2013) The genomes of four tapeworm species reveal adaptations to parasitism. Nature 496: 57–63. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3964345&tool=pmcentrez&rendertype=abstract. Accessed 11 July 2014. doi: 10.1038/nature12031 23485966
122. Desjardins CA, Cerqueira GC, Goldberg JM, Dunning Hotopp JC, Haas BJ, et al. (2013) Genomics of [i]Loa loa[/i], a Wolbachia-free filarial parasite of humans. Nat Genet 45: 495–500. Available: http://dx.doi.org/10.1038/ng.2585. Accessed 30 September 2014. doi: 10.1038/ng.2585 23525074
123. Cwiklinski K, Dalton JP, Dufresne PJ, La Course J, Williams DJ, et al. (2015) The [i]Fasciola hepatica[/i] genome: gene duplication and polymorphism reveals adaptation to the host environment and the capacity for rapid evolution. Genome Biol 16: 71. http://genomebiology.com/2015/16/1/71. Accessed 7 April 2015. doi: 10.1186/s13059-015-0632-2 25887684
124. Carlton JM, Hirt RP, Silva JC, Delcher AL, Schatz M, et al. (2007) Draft genome sequence of the sexually transmitted pathogen [i]Trichomonas vaginalis[/i]. Science 315: 207–212. http://www.sciencemag.org/content/315/5809/207.full. Accessed 30 September 2014. 17218520
125. Adam RD, (2000) The Giardia lamblia genome. Int J Parasitol 30: 475–484. http://www.ncbi.nlm.nih.gov/pubmed/10731570. Accessed 20 October 2014. 10731570
126. Franzén O, Jerlström-Hultqvist J, Castro E, Sherwood E, Ankarklev J, et al. (2009) Draft genome sequencing of giardia intestinalis assemblage B isolate GS: is human giardiasis caused by two different species? PLoS Pathog 5: e1000560. http://dx.plos.org/10.1371/journal.ppat.1000560. Accessed 20 October 2014. doi: 10.1371/journal.ppat.1000560 19696920